OverviewSuggest Edit

Edwards Lifesciences is a company operating as a global provider of patient-focused medical solutions for structural heart disease and critical care monitoring. The company develops heart valve therapies and manufactures heart valve systems and repair products used to replace or repair diseased or defective heart valves. It also offers hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

TypePublic
Founded1958
HQIrvine, CA, US
Websiteedwards.com
Employee Ratings4
Overall CultureB+

Latest Updates

Employees (est.) (Dec 2019)13,900(+9%)
Job Openings564
Revenue (FY, 2020)$4.4 B
Share Price (Apr 2021)$97.4(+2%)
Cybersecurity ratingBMore

Key People/Management at Edwards Lifesciences

Donald E. Bobo

Donald E. Bobo

Corporate Vice President, Strategy & Corporate Development
Michael A. Mussallem

Michael A. Mussallem

Chairman, Chief Executive Officer
Todd J. Brinton

Todd J. Brinton

Corporate Vice President, Advanced Technology, Chief Scientific Officer
Daveen Chopra

Daveen Chopra

Corporate Vice President, Surgical Structural Heart
Dirksen J. Lehman

Dirksen J. Lehman

Corporate Vice President, Public Affairs
Jean-Luc Lemercier

Jean-Luc Lemercier

Corporate Vice President, EMEA, Canada and Latin America
Show more

Edwards Lifesciences Office Locations

Edwards Lifesciences has offices in Irvine, Draper, Washington, Macquarie Park and in 36 other locations
Irvine, CA, US (HQ)
1 Edwards Way
Draper, UT, US
12050 Lone Peak Pkwy
Washington, DC, US
601 13th St NW #350
Macquarie Park, AU
40 Talavera Rd
Wien, AT
Vorgartenstraße 206C
Dilbeek, BE
Pontbeekstraat 4
Show all (41)

Edwards Lifesciences Financials and Metrics

Edwards Lifesciences Revenue

Embed Graph
View revenue for all periods
Edwards Lifesciences's revenue was reported to be $4.39 b in FY, 2020
USD

Revenue (FY, 2020)

4.4b

Gross profit (FY, 2020)

3.3b

Gross profit margin (FY, 2020), %

75.4%

Net income (FY, 2020)

823.4m

EBIT (FY, 2020)

897.6m

Market capitalization (23-Apr-2021)

60.0b

Closing stock price (23-Apr-2021)

97.4

Cash (31-Dec-2020)

1.2b

EV

59.0b
Edwards Lifesciences's current market capitalization is $60 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

3.4b3.7b4.3b4.4b

Revenue growth, %

8%17%

Cost of goods sold

875.3m939.4m1.1b1.1b

Gross profit

2.6b2.8b3.2b3.3b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

894.8m943.7m906.6m993.0m1.1b1.1b1.1b1.1b

Cost of goods sold

233.6m246.2m224.9m231.8m304.0m292.4m265.1m238.2m

Gross profit

661.2m697.5m681.7m761.2m782.9m801.6m863.6m

Gross profit Margin, %

74%74%75%77%72%73%77%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

818.3m714.1m1.2b1.2b

Accounts Receivable

421.6m456.9m543.6m514.6m

Prepaid Expenses

60.6m54.3m59.1m75.1m

Inventories

554.9m607.0m640.9m802.3m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

1.2b1.2b1.3b709.2m726.8m1.2b662.9m903.5m

Accounts Receivable

406.6m431.4m423.8m585.1m567.9m549.7m

Prepaid Expenses

78.0m69.9m52.6m55.4m55.7m57.3m65.8m57.3m68.6m

Inventories

573.9m568.1m583.8m630.9m624.9m611.1m662.2m735.1m773.3m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

583.6m722.2m1.0b823.4m

Depreciation and Amortization

81.9m77.4m89.3m107.2m

Inventories

(124.0m)(65.7m)(105.4m)(120.6m)

Accounts Payable

85.2m192.5m(63.5m)(84.5m)
Quarterly
USDFY, 2017

Revenue/Employee

281.6k

Debt/Equity

0.4 x

Debt/Assets

0.2 x

Financial Leverage

1.9 x
Show all financial metrics

Edwards Lifesciences Operating Metrics

FY, 2017FY, 2018FY, 2019

Manufacturing Facilities

777

Patents and Patent Applications

3.6 k3.9 k4.7 k
Show all operating metrics

Edwards Lifesciences Acquisitions / Subsidiaries

Company NameDateDeal Size
CAS Medical SystemsFebruary 11, 2019$100.8 m
Harpoon MedicalDecember 01, 2017$119.5 m
Valtech CardioJanuary 23, 2017$352.7 m
CardiAQ Valve TechnologiesAugust 26, 2015$348 m
BMEYEOctober 09, 2012€28.4 m
Embrella CardiovascularMarch 11, 2011$42.6 m
MyocorOctober 09, 2008
Percutaneous Valve TechnologiesJanuary 27, 2004$125 m
Whitland ResearchDecember 05, 2003$3.2 m
Edwards Lifesciences AG
Show more

Edwards Lifesciences Revenue Breakdown

Embed Graph

Edwards Lifesciences revenue breakdown by business segment: 17.0% from Critical Care, 19.4% from Surgical Structural Heart, 63.0% from Transcatheter Aortic Valve Replacement and 0.6% from Other

Edwards Lifesciences revenue breakdown by geographic segment: 21.6% from Europe, 9.9% from Rest of World, 10.2% from Japan and 58.2% from United States

Edwards Lifesciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Edwards Lifesciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Edwards Lifesciences Online and Social Media Presence

Embed Graph

Edwards Lifesciences Company Culture

  • Overall Culture

    B+

    85/100

  • CEO Rating

    A+

    95/100

  • Compensation

    B

    78/100

Learn more on Comparably

Edwards Lifesciences News and Updates

‘Double-Digit’ Growth Could Boost Edwards Lifesciences Stock

Edwards expects to resume double digit growth as a robust product pipeline gets to market

Thinking about buying stock in Aurora Cannabis, Boeing, Edwards Lifesciences, First Solar, or Toll Brothers?

NEW YORK, Jan. 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, BA, EW, FSLR, and TOL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ACB:...

Edwards Lifesciences To Present At The 38th Annual J.P. Morgan Healthcare Conference

IRVINE, Calif., Jan. 8, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is scheduled to present at the J.P. Morgan Healthcare Conference at the Westin St. Francis...

Edwards Lifesciences Would Make Peter Drucker Smile

Edwards Lifesciences makes the world better for employees, patients, and communities. With its stock up 164% over the last three years, it has further to go.

UPDATE 2-FDA pegs Edwards Lifesciences Sapien delivery system recall as severest

The U.S. health regulator on Thursday categorized the recall of Edwards Lifesciences Corp's Sapien 3 Ultra delivery system as extremely serious, highlighting health risks associated with its use, but the products will remain on the market.

Edwards Lifesciences Reports Second Quarter Results

IRVINE, Calif., July 23, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2019. Second Quarter and...
Show more

Edwards Lifesciences Blogs

Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021

Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021 Content Import Tue, 04/13/2021 - 07:05 Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021 April 13, 2021 at 7:05 AM EDT This release is a backfill from a News Wire …

Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years

AUSTIN, Texas , Jan. 31, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards' bioprosthetic surgical aortic valve with the company's novel RESILIA tissue platform show favorable safety and hemodynamic performance

Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021

Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021 Content Import Wed, 01/13/2021 - 07:05 Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021 January 13, 2021 at 7:05 AM EST This release is a backfill from a News Wi…

Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease

IRVINE, Calif. , Dec. 21, 2020 /PRNewswire/ --  Edwards Lifesciences (NYSE: EW), today announced that the first patient has been treated in the RESTORE clinical trial, which will evaluate the safety and effectiveness of the investigational HARPOON Beating Heart Mitral Valve Repair System in the

Edwards Lifesciences To Host Earnings Conference Call On October 21, 2020

Edwards Lifesciences To Host Earnings Conference Call On October 21, 2020 Content Import Wed, 10/07/2020 - 10:05 Edwards Lifesciences To Host Earnings Conference Call On October 21, 2020 October 7, 2020 at 10:05 AM EDT This release is a backfill from a News Wi…

Paul LaViolette

Paul LaViolette kevindavis Wed, 07/15/2020 - 10:42 Member of the Compensation and Governance Committee Paul A. LaViolette Paul A. LaViolette, age 63, has been a director of the Company since July 2020. Mr. LaViolette brings 40 years of experience in global …
Show more

Edwards Lifesciences Frequently Asked Questions

  • When was Edwards Lifesciences founded?

    Edwards Lifesciences was founded in 1958.

  • Who are Edwards Lifesciences key executives?

    Edwards Lifesciences's key executives are Donald E. Bobo, Michael A. Mussallem and Todd J. Brinton.

  • How many employees does Edwards Lifesciences have?

    Edwards Lifesciences has 13,900 employees.

  • What is Edwards Lifesciences revenue?

    Latest Edwards Lifesciences annual revenue is $4.4 b.

  • What is Edwards Lifesciences revenue per employee?

    Latest Edwards Lifesciences revenue per employee is $315.6 k.

  • Who are Edwards Lifesciences competitors?

    Competitors of Edwards Lifesciences include Zimmer Biomet, Bristol-Myers Squibb and Livanova.

  • Where is Edwards Lifesciences headquarters?

    Edwards Lifesciences headquarters is located at 1 Edwards Way, Irvine.

  • Where are Edwards Lifesciences offices?

    Edwards Lifesciences has offices in Irvine, Draper, Washington, Macquarie Park and in 36 other locations.

  • How many offices does Edwards Lifesciences have?

    Edwards Lifesciences has 41 offices.